BioNTech & Bristol Myers Squibb report 36.7% response rate for experimental lung cancer drug

Bristol Myers Squibb (BMY) reported positive Phase III trial results for its licensed anticancer drug izalontamab brengitecan, showing extended progression-free survival in NSCLC patients. The company licensed the drug from SystImmune, paying $800M upfront and potentially up to $7.1B in milestones. Despite the positive data, BMY's stock rose marginally, as the trial was conducted in China and overall survival data is immature. The FDA typically requires multi-regional data for approval.

Bristol Myers Squibb (BMY) reported positive Phase 3 trial results for its cancer drug izalontamab brengitecan, showing a median progression-free survival of 11.1 months vs. 5.7 months for chemotherapy. The drug, licensed from SystImmune, demonstrated a manageable safety profile. BMY shares rose 0.21% on the news, though investors remain cautious due to regulatory hurdles and immature overall survival data. The company paid $800M upfront and could pay up to $7.1B in milestones.

Moderna (MRNA) shares fell 20% after leaked trial data for its melanoma vaccine, despite analysts calling results 'strong.' The drop may signal the end of its 700% year-to-date rally. Merck (MRK), partnering on the vaccine, saw minimal impact. Analysts expect Merck to report strong earnings. BioNTech (BNTX) and Illumina (ILMN) are also mentioned.

Bristol Myers Squibb (BMS) reported a patient death in its Phase I trial of zolacabtagene autoleucel for multiple sclerosis, stating it was unrelated to prior study pauses. Pathos AI partnered with BMS and Tempus AI to develop an AI-driven dataset for Alzheimer’s, with BMS leading a $237M Series E round valuing Pathos at $3B. Dr. Nadine Zawadzki discussed value-based care in healthcare on The Ron Lanton Report.

BioNTech and DualityBio report that trastuzumab pamirtecan (BNT323/DB-1303) met its primary end point of progression-free survival in a phase 3 trial for HR-positive, HER2-low metastatic breast cancer. The trial enrolled 541 patients, with interim analysis showing improved PFS over chemotherapy. Interstitial lung disease occurred at a higher rate, but no new safety signals were observed. The companies will determine next steps for development.

Bristol Myers Squibb reported a death in a multiple sclerosis trial of its experimental therapy zola-cel, citing late-onset motor symptoms and septic pneumonia. The company noted no other deaths in related trials. Meanwhile, the U.S. Treasury proposed new rules to scrutinize U.S. investments in China's biotech sector, potentially affecting cross-border deals.